ALK-Positive Non-Small Cell Lung CancerSymptoms, Doctors, Treatments, Advances & More
Learn About ALK-Positive Non-Small Cell Lung Cancer
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Vince Lombardi Cancer Clinic
Demet Yasar is a Hematologist in Green Bay, Wisconsin. Dr. Yasar is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. Her top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Pleuropulmonary Blastoma, and Myelodysplastic Syndrome (MDS).
Advocate Lutheran General Cancer Institute
Jason Macklis is a Hematologist and an Oncologist in Park Ridge, Illinois. Dr. Macklis is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Bone Marrow Aspiration.
SOFHA Pulmonology
. Dr. Garcia is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. Her top areas of expertise are Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Asthma in Children, Lung Nodules, and Advanced Bronchoscopy.
Summary: This phase I trial is studying the safety, side effects, and best dose of gilteritinib in treating patients with stage IV ALK positive non-small cell lung cancer (NSCLC) who have progressed on other treatments. While there are many approved targeted drugs for ALK NSCLC, resistance to these drugs frequently occur. Giltertinib is a drug that is already FDA approved for the treatment of a specific ty...
Summary: This is a study of brigatinib in adults with Non-Small Cell Lung Cancer (NSCLC). The main aim of this study is to learn about the time period in which the condition does not worsen after the participant has received brigatinib. Another aim is to learn about the overall rate of participants who respond to the treatment with brigatinib. Participants will receive brigatinib as part of their normal cl...